ArticleRheumatology (Oxford, England)2025
Stratification of systemic lupus erythematosus with IGHV4-34 in unswitched memory B cells.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Autoreactive B cells in systemic lupus erythematosus: insights from integrative multi-omics analyses.Inflammation and regeneration · 2026Review
- Molecular characterisation of telitacicept response phenotypes in systemic lupus erythematosus: an exploratory integrated transcriptome and B-cell receptor repertoire profiling study.Journal of translational medicine · 2026Article
- Article
- Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathways.Rheumatology (Oxford, England) · 2026Observational
- T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesSLE is an autoimmune disease characterized by the production of autoantibodies. Antibody affinities are defined by immunoglobulins, which include the immunoglobulin heavy-chain variable region (IGHV) genes, but the relationship between SLE and IGHV has not been fully elucidated. This study aimed to investigate the association between clinical features of SLE and IGHV.
methodsWe recruited SLE patients and collected their peripheral blood. B cells from SLE patients were sorted into naïve B cells, unswitched memory (USM) B cells, switched memory B cells, double-negative B cells and plasmablasts. RNA-seq was performed to analyse IGHV gene usage, calculating the frequency of clonotypes that use IGHV4-34. The interactions between IGHV4-34 usage and clinical features were analysed by regression analysis, and the threshold for stratifying SLE patients by IGHV4-34 usage was determined by receiver operating characteristic (ROC) analysis.
resultsIGHV4-34 usage in USM B cells had a significant association with disease activity. ROC curve analysis revealed the threshold of IGHV4-34 usage in USM B cells which distinguished patients with low complement levels from the other patients. High IGHV4-34 usage in USM B cells was associated with arthritis, haematuria, proteinuria, rash and fever. Achievement of a lupus low disease activity state (LLDAS), SLEDAI 2000 score and physician global assessment score showed worse values in the high IGHV4-34 usage group. Among those who achieved LLDAS under tacrolimus treatment, patients with high IGHV4-34 usage in USM B cells had a higher flare rate.
conclusionIGHV4-34 usage in USM B cells is a potential biomarker of SLE and for patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.